Parthanatos is a programmed necrotic demise characteristic of ATP (adenosine triphosphate) consumption due to NAD + (nicotinamide adenine dinucleotide) depletion by poly(ADP-ribose) polymerase 1 (PARP1)-dependent poly(ADP-ribosyl)ation on target proteins. However, how the bioenergetics is adaptively regulated during parthanatos, especially under the condition of macroautophagy deficiency, remains poorly characterized. Here, we demonstrated that the parthanatic inducer N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) triggered ATP depletion followed by recovery in mouse embryonic fibroblasts (MEFs). Notably, Atg5 −/− MEFs showed great susceptibility to MNNG with disabled ATP-producing capacity. Moreover, the differential energy-adaptive responses in wild-type (WT) and Atg5 −/− MEFs were unequivocally worsened by inhibition of AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1), and mitochondrial activity. Importantly, Atg5 −/− MEFs disclosed diminished SIRT1 and mitochondrial activity essential to the energy restoration during parthanatos. Strikingly, however, parthanatos cannot be exasperated by bafilomycin A1 and MNNG neither provokes microtubule-associated protein 1A/1B-light chain 3 (LC3) lipidation and p62 elimination, suggesting that parthanatos does not induce autophagic flux. Intriguingly, we reported unexpectedly that PD98059, even at low concentration insufficient to inhibit MEK, can promote mitochondrial activity and facilitate energy-restoring process during parthanatos, without modulating DNA damage responses as evidenced by PARP1 activity, p53 expression, and γH2AX (H2A histone family, member X (H2AX), phosphorylated on Serine 139) induction. Therefore, we propose that Atg5 deficiency confers an infirmity to overcome the energy crisis during parthanatos and further underscore the deficits in mitochondrial quality control, but not incapability of autophagy induction, that explain the vulnerability in Atg5-deficient cells. Collectively, our results provide a comprehensive energy perspective for an improved treatment to alleviate parthanatos-related tissue necrosis and disease progression and also provide a future direction for drug development on the basis of PD98059 as an efficacious compound against parthanatos.
Introduction
Parthanatos is a particular type of programmed necrosis characterized by the death signal poly(ADP-ribose) (PAR) polymers, poly(ADP-ribose) polymerase (PARP)-mediated PAR accumulation, ATP and NAD + depletion, mitochondrial perturbation, and apoptosisinducing factor (AIF) nuclear translocation from mitochondria [1] [2] [3] [4] .
Among all PARP superfamily, PARP1 is the most abundant protein localized in the nucleus that could immediately respond to the DNA damage, such as alkylation or double-strand breaks, to promote DNA repair machinery through NAD + -dependent PARylation on acceptor proteins, such as histones and PARP1 itself [5, 6] . However, if the DNA damage is irreparable, PARP1 over-activation will culminate in PARP1-dependent parthanatic cell death. Widespread as an environmental mutagen, N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) is such a commonly used DNA-alkylating agent that potently initiates parthanatic cell death in a caspase-independent manner [3] . In our previous study, we have confirmed that MNNG is able to induce AIF nuclear translocation and necrotic cell death in mouse embryonic fibroblasts (MEFs) [7] . Moreover, the cell death was prevented by PARP1 inhibitors such as 3-aminobenzamide (3AB) and 3,4-dihydro-5 [4-(1-piperindinyl) butoxy]-1(2H)-isoquinoline (DPQ), implicating MNNG-induced cell death due to PARP1 over-activation [7] .
Parthanatos has been implicated in several pathological conditions, such as neurodegenerative disorders including Parkinson's and Alzheimer's diseases, glutamate excitotoxicity, stroke, ischemia-reperfusion injury, and diabetes mellitus [8] [9] [10] [11] [12] . Many efforts have been spent to understand this distinct type of cell death to hinder from extensive tissue inflammation and disease progression [12] . Besides several parthanatic hallmarks already defined [2] , mitogen-activated protein kinase (MAPK) signaling pathways such as JNK and p38 have also been implied to regulate the parthanatic responses [13, 14] . Considering the energy depletion as an essential biochemical feature, enforced repletion of metabolic intermediates has been utilized to prevent from parthanatic cell death in neurons and astrocytes [15, 16] . Despite the current progress in our understandings about parthanatos, the need for efficacious PARP inhibitors of better therapeutic potential is emerging [17] . Currently, the crystal structure of a DNA double-strand break in complex with human PARP1 domains obligatory for activation has been resolved [18] , which may facilitate the process in designing novel PARP1 inhibitors.
Macroautophagy (hereafter termed autophagy) is highly coordinated self-digesting process involving autophagosomal engulfment and lysosomal degradation of damaged proteins or organelles for recycling to maintain intracellular energy homeostasis under normal physiological condition or in response to certain stress stimuli [19, 20] . Derangement of autophagy has a pathogenic contribution to several diseases, like infection, cancer, neurodegeneration, heart diseases, and aging [21] [22] [23] [24] [25] .
Currently, however, less is known about the regulation of energy turnover during parthanatos. Considering autophagy is a self-protective scheme in response to stress for energy preservation and parthanatos is a cell death process associated with energy depletion, we were interested in understanding the role of autophagy in energy regulation during parthanatos. Moreover, inspired by the concomitant occurrences of autophagy dysregulation and parthanatos in neurodegenerative and cardiovascular disorders, we speculated that autophagy defects may amplify the severity of parthanatic cell death. In this study, we tried to elucidate the contribution of autophagy dependency as well as the elsewhere mentioned MAPK pathways to energy homeostasis and severity during parthanatos in MEFs. Here, we demonstrate for the first time that Atg5 −/− MEFs are extremely susceptible to MNNG and that PD98059, a traditionally known MEK inhibitor, shows an unexpected protectiveness and saves the vulnerable MEFs during parthanatos in a MEK-independent manner. On the other hand, we also highlight the indispensable roles of AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1), and mitochondrial activity in regulating energy restoration during parthanatos, which also better explain the differential response in Atg5-deficient cells. Collectively, these results provide a complete energy perspective for better treating parthanatos-related disorders and reveal unexpectedly PD98059 as an effective parthanatosalleviating compound that should guide the future direction for drug development.
Materials and methods

Reagents and antibodies
MNNG (O-2392) was purchased from Chem Service. 7-Aminoactinomycin D (7AAD, 559925) was obtained from BD Pharmingen. zVAD-fmk (219007), doxorubicin (324380), SB203580 (559389), SP600125 (420119), U0126 (662005), PD98059 (513000), wortmannin (681675), and compound C (171260) were ordered from Calbiochem. Gallotannin (403040), rapamycin (R8781), bafilomycin A1 (B1793), rotenone (R8875), diphenyliodonium (DPI, D2926), trifluorocarbonylcyanide phenylhydrazone (FCCP, C2920), MTT (M2128) and Dulbecco's PBS (D5652) were obtained from Sigma-Aldrich. JC-1 (T3168), Dulbecco's Modified Eagle Medium (DMEM, 12100-046), trypsin-EDTA (25200-072), fetal bovine serum (FBS, 04001-1A), and penicillin/streptomycin (03031-1B) were purchased from Invitrogen. The FastStart Universal SYBR Green Master (14526100) was ordered from Roche Applied Science. Commercial antibodies against p-ERK1/2 (Thr202/Tyr204, 9101), p-JNK (Thr183/Tyr185, 9251), p-p38 (Thr180/ Tyr182, 9211), p53 (9282), p-AMPKα1 (Thr172, 2531), AMPKα1 (2532), p-GSK3β (Ser9, 9336), p-Akt (Ser473, 9271), Akt (9272), and SQSTM1/p62 (5114) were purchased from Cell Signaling Technology (Beverly, MA, USA); GSK3β (sc-9166), ERK1/2 (sc-292838), JNK1 (sc-474), and p38 (sc-7149) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); Atg5 antibody (ab54033-100) was purchased from Abcam; β-actin antibody (MAB1501) was purchased from Upstate Biotechnology; PAR antibody (551813) was purchased from BD Pharmigen; γH2AX antibody (05-636) was ordered from Merck Millipore; LC3 antibody (PM036) was purchased from MBL. Normal rabbit IgG and horseradish peroxidase-conjugated antibodies (sc-2004) were purchased from Santa Cruz Biotechnology. Enhanced chemiluminescence (ECL) reagent was ordered from Perkin Elmer.
Cell culture
Atg5
+/+ and Atg5 −/− MEFs were kindly provided by Dr. Noburu
Mizushima (Tokyo Medical and Dental University). Primary WT and PARP1 −/− MEFs were isolated from fresh 129S WT and 129S PARP1
−/− mice, respectively. HeLa cells were purchased from the American Type Culture Collection (Manassas, VA, USA). MEFs and HeLa cells were cultured in high-glucose DMEM supplemented with 10% heatinactivated FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. The cells were incubated at 37°C in a humidified atmosphere with 5% CO 2 .
Intracellular ATP assay
Intracellular ATP was determined by CellTiter-Glo® Luminescent Kit (G7571) from Promega according to the manufacturer's protocol. In brief, 5 × 10 4 cells were seeded per well in a 24-well plate for 24 h followed by the treatment indicated. Medium was then replaced with the new one, and the reagent was added to lyze the cells. The plate was gently shaken for 2 min, placed stationary in the dark for 10 min, and then 150 μl solution was transferred to a 96-well plate for luminescence detection using LB96V MicroLumat Plus (American Laboratory Trading). With background subtraction, the values were normalized to individual control group as 100%.
Determination for 7AAD + cells
MEFs were seeded in a 24-well plate (5 × 10 4 cells per well) for 24 h followed by the treatment indicated. The supernatant was collected, and the cells were trypsinized and then mixed with the respective supernatant, followed by centrifugation at 2500 rpm for 10 min at room temperature. The pelleted cells were washed with 1 × PBS once and then centrifuged in a similar manner. Then, the cells were resuspended with PBS containing 7AAD (5 μM) and then submitted to FACS analysis (FACScan flow cytometer, Becton Dickinson) using the CellQuest program. The data were obtained based on the FL3 channel.
Lactate dehydrogenase (LDH) release assay
LDH release assay was performed using CytoTox 96® Non-Radioactive Cytotoxicity Assay Kit (G1780) from Promega according to the manufacturer's protocol. In brief, cells were seeded in a 24-well plate (5 × 10 4 cells per well) for 24 h followed by the treatment as indicated.
The readout for the maximum LDH release was achieved by Lysis Solution (10 ×) 45 min before the endpoint. The supernatant from each well was collected and centrifuged for 5 min at 4°C, and then transferred in 50 μl into a 96-well plate, followed by 50 μl reconstituted substrate mix, for a desired incubation period (protected from light).
A final 50 μl stop solution was added into each well, and the plate was read at 490 nm. With background subtraction, the maximum value was represented by the complete lysis group as 100%.
Immunoblot
Cells were lyzed with the RIPA buffer supplemented with a cocktail of proteinase inhibitors. After sonication, protein concentrations were determined using the Bio-Rad protein assay. Each sample with the equal protein concentration was electrophoresed on SDS-PAGE, and transferred to the PVDF membranes. Nonspecific binding was blocked with 5% nonfat milk. After immunoblotted with the primary specific antibodies as indicated, membranes were washed and incubated with an HRP-conjugated secondary antibody. Protein bands were detected with an enhanced chemiluminescence detection reagent. The signals were quantified by ImageJ 1.48 g with suitable background calibration and represented as indicated the ratio of respective intensity units.
Immunoprecipitation for SIRT1 activity assay
SIRT1 activity was measured by CycLex Sir2 Assay Kit (CY-1151) from MBL International Corporation according to the manufacturer's protocol. In brief, after SIRT1 immunoprecipitation, a mixture of SIRT1 reaction agents was added and incubated for 1 h. Finally, 50 μl supernatant per sample was transferred into a 96-well dark plate, followed by 50 μl 2 × Stop Solution. At this time, a blank (Cell Lysis Buffer alone) and a recombinant SIRT1 were used as background correction. Fluorescence was read by LB96V MicroLumat Plus with excitation wavelength at 340-360 nm and emission at 440-460 nm. Data were normalized to the protein content measured by Bradford method and expressed as % compared to the WT control group (100%).
Mitochondrial DNA (mtDNA) quantification
After drug treatment, the cell pellet was added with UniversALL™ Extraction Buffer (Yeastern, Cat. YGF10-1) and heated for 10 min at 95°C for complete extraction of total DNA, and DNA concentration was quantified by the LB96V MicroLumat Plus at 260 nm and 280 nm. A total of 1 μg DNA was used, mixed well with the FastStart SYBR Green Master (Roche), and then submitted to quantitative real-time PCR analysis with automatic C T setting, with a program of 20 min at 95°C, followed by 50 cycles for 15 s at 95°C, 20 s at 58°C and 20 s at 72°C. Single-product amplification was verified by an integrated postrun melting curve analysis. The primer sequence pairs used for quantitative real-time PCR were mtDNA (16S rRNA) forward 5′-AGCTG AAGAA AGCGT GTTCC A-3′, mtDNA (16S rRNA) reverse 5′-AACTC TGTCC AAGAT CGCTG ACT-3′, nuclear DNA (hexokinase 2, intron 9) forward 5′-CGGGG ACCTG ACTGA CTACC-3′ and nuclear DNA (hexokinase 2, intron 9) reverse 5′-AGGAA GGCTG GAAGA GTGC-3′. mtDNA content was calculated from the difference in C T values between mtDNA and nucleus-specific DNA and expressed as fold increase based on a 2 −△△CT method.
RNA extraction, reverse transcription, and quantitative real-time PCR
RNA extraction and real time-PCR were conducted as we previously described [26] . The primer sequence pairs used for quantitative realtime PCR were PGC1α forward 5′-AGCCGTGACCACTGACAACGAG-3′, PGC1α reverse 5′-GCTGC ATGGT TCTGA GTGCT AAG-3′; β-actin forward 5′-CGGGG ACCTG ACTGA CTACC-3′, β-actin reverse 5′-AGGAA GGCTG GAAGA GTGC-3′.
MTT assay
MEFs (5 × 10
4 per well) were seeded in a 24-well plate for 24 h followed by the treatment as indicated. At the endpoint, MTT solution (5 mg/ml) was added into the medium per well with a 5-fold dilution, and the plate was incubated for 1 h at 37°C. After that, the solution was aspirated, and the purple formazan granules metabolized by the mitochondria in live cells were resolved with 300 μl DMSO. The signal was detected by LB96V MicroLumat Plus (American Laboratory Trading) at 550 and 630 nm. Data were represented by A 550-630 and normalized with the individual control group as 100%.
Determination for mitochondrial transmembrane potential (MTP, △ Ψ m )
JC-1 dye was used to detect △Ψ m by FACS analysis. If △Ψ m is maintained, JC-1 forms as a dimer and reveals red; otherwise, when △Ψ m is disrupted, JC-1 acts as a monomer and the red color declines into an orange or yellow color. Of note, additional rotenone-treated and FCCP-treated groups were used as positive controls. After drug treatment, medium was aspirated, replaced with PBS containing JC-1 (5 μg/ml) for 30 min at 37°C in the dark. The cells were then trypsinized and transferred into a micro-centrifuge tube, centrifuged at 2500 rpm for 10 min, resuspended as a single-cell suspension, followed by FACS analysis (FACScan flow cytometer, Becton Dickinson) using the CellQuest program. The data were obtained based on the FL1 (on the x-axis) and FL2 (on the y-axis) channels with appropriate compensation, and expressed as the cell percentage with significant loss of FL-2 signal under the user-defined quadrant analysis.
Statistical analysis
All statistical analyses were performed with unpaired two-tailed Student's t-tests. Values were expressed as the mean ± S.E.M. from at least three independent experiments, each of which was done in 2-3 replicates.
Results
Atg5
−/− MEFs are vulnerable to MNNG-induced cell death
The parthanatos inducer MNNG triggered the ATP depletion within 4 h treatment followed by a recovery phase in MEFs, where Atg5
MEFs showed impaired ATP restoration compared to the WT counterpart (Fig. 1A ). Similar to our previously work demonstrating that MNNG-induced PARylation and necrotic cell death in MEFs could be abrogated by the pharmacological inhibitors 3AB and/or DPQ [7] , we also confirmed this notion in terms of ATP depletion. Our data revealed that MNNG-induced early-phase ATP depletion could be completely abrogated by the PARP1 inhibitor 3AB (Fig. 1B) or in the absence of PARP1 (Fig. 1C) . In support of necrotic context, MNNG-elicited ATP dynamic alteration was not affected in the presence of pan-caspase inhibitor zVAD-fmk (Fig. 1D) . Consistent with the fragility in MNNG-treated Atg5 −/− MEFs, LDH release was detectable at 9 h and up to 60% at 24 h (Fig. 1E) . Similarly, by use of 7AAD, which could intercalate double-stranded nucleic acids from dying and dead cells, we demonstrated that Atg5 −/− MEFs showed more 7AAD + signals in response to MNNG than the WT counterpart (Fig. 1F) . Furthermore, we confirmed this biphasic ATP alteration is specific to MNNG in MEFs, where both WT and Atg5 −/− MEFs similarly responded to the topoisomerase inhibitors doxorubicin (Fig. 1G ) and etoposide (Fig. 1H) . Taken together, these data suggest that Atg5 −/− MEFs are vulnerable to MNNG-induced cell death with disabled ATP recovery.
MAPKs do not regulate energy adaptive response during parthanatos in MEFs
As previously mentioned in other contexts [13, 14] , we also wondered whether MAPKs have a role in energy adaptation during parthanatos in MEFs. Phosphorylation of ERK, JNK and p38 was similarly induced in
WT and Atg5
−/− MEFs in response to MNNG ( Fig. 2A) . Moreover, SB203580 (a p38 inhibitor) (Fig. 2B ), SP600125 (a JNK inhibitor) ( Fig. 2C ) and U0126 (a MEK/ERK inhibitor) (Fig. 2D) (Fig. 2E ).
PD98059 effectively facilitates ATP restoration during parthanatos and saves vulnerable MEFs in a MEK-independent manner
In the above MAPK screen, we discovered unexpectedly that PD98059, a flavonoid derivative considered the conventional MEK/ERK inhibitor, effectively and dose-dependently facilitated ATP recovery (Fig. 3A) and dampened cell death (Fig. 3B ) in response to MNNG evidently in vulnerable Atg5 −/− MEFs at the concentration as low as 3 μM. Notably, MNNG-induced ERK1/2 phosphorylation was not attenuated by PD98059 at 10 μM, neither JNK nor p38 phosphorylation ( Fig. 3C  and D) . Notably, inhibition of ERK phosphorylation could be readily achieved by U0126 at 3 μM (Fig. 3C) , while only partially achieved by PD98059 at 30 μM (Fig. 3D) . Furthermore, post-treatment of PD98059 (10 μM) at 1 and 4 h after MNNG administration rendered the similar protectiveness as pre-treatment (Fig. 3E) . Collectively, these data implied PD98059 as an effective parthanatos-inhibiting compound whose protectiveness is through a MEK-independent mechanism.
PD98059 protects MNNG-treated MEFs without modulation on DNA damage responses
We questioned whether protection by PD98059 at effective dosage against parthanatos comes from modulation of MNNG-elicited PARP1 activation and DNA damages in MEFs. To address these possibilities, we first determined PARP1-dependent PARylation as an index of PARP1 activity. Administration of MNNG rapidly induced PARylation of several proteins, especially with the apparent effect on protein(s) at the same molecular weight as PARP1 (113 kD) ( Fig. 4A and B) . As PARP1 itself can undergo PARylation [27] , this obvious PARylation signal might be representative of PARP1 and its activity. Importantly, we found that PARP1 PARylation following MNNG treatment was unaffected in the presence of PD98059 in both WT and Atg5 −/− MEFs, albeit a higher PAR signal was noted in Atg5 −/− MEFs (Fig. 4B) . This PARP1 PARylation after MNNG treatment was neither significantly affected by PD98059 at higher concentration (30 μM) when ERK inhibition was achieved (Fig. 4A) . Next, to further evaluate if PD98059 might affect MNNGinduced DNA damage responses, we determined p53 and γH2AX expression. We found that MNNG-induced p53 protein expression in both WT and Atg5 -/− MEFs was neither disturbed by PD98059 nor U0126 (Fig. 4C) and ditto for γH2AX expression in WT MEFs (Fig. 4D) .
To test whether PD98059 could still be protective under enhanced death signal, we utilized the poly(ADP-ribose) glycohydrolase (PARG) inhibitor gallotannin (GLTN) for PAR retention. Within 8 h screening, ATP restoration following MNNG treatment was significantly impaired in the presence of GLTN in both MEFs, while addition of PD98059 in context with GLTN still facilitated ATP recovery in both WT and Atg5
MEFs (Fig. 4E) . Therefore, these data argue that PD98059 protects MEFs from parthanatos without modulation on DNA damage responses.
AMPK is indispensable to energy adaptation during parthanatos
Since the energy stress is a clear signature of parthanatos, we turned to examine other master stress kinases about their contribution to parthanatic energy responses in MEFs. Western blot analysis demonstrated that phosphorylation of AMPKα1 at Thr172 was induced as early as 30 min after MNNG administration in MEFs, but faded down thereafter (Fig. 5A) . Here, we noted a higher basal AMPKα1 phosphorylation in Atg5 −/− MEFs. Within 30 min challenge, the levels of phosphorylation on Akt at Ser473 and GSK3β at Ser9 decreased whenever AMPK was active (Fig. 5A) , suggesting a reciprocal activation relationship between AMPK and Akt/GSK3β signal pathways immediately after MNNG administration. After this early inhibitory response, the Akt and GSK3β phosphorylation statuses concordantly rebounded (Fig. 5A) . However, in the presence of PD98059, the phosphorylation dynamics of these kinases inducible by MNNG was not significantly affected in both MEFs (Fig. 5A) . To understand the essential role of AMPK in energy regulation upon parthanatos, we used the pharmacologic AMPK inhibitor compound C. Indeed, in the presence of compound C, the ATP restorability during parthanatos was both impaired in WT and Atg5 −/− MEFs (Fig. 5B) . Remarkably, addition of PD98059 still facilitated ATP recovery in MNNG-challenged WT and Atg5 −/− MEFs in the presence of compound C (Fig. 5B) . On the other hand, pharmacologic inhibition of PI3K/Akt by wortmannin or mTORC1 by rapamycin only slightly worsened the energy restoration in MNNG-treated Atg5
MEFs, not comparable to that caused by compound C (Fig. 5C ). Consistently, LDH release was aggravated in both MEFs by compound C, whereas addition of PD98059 alleviated this aggravation (Fig. 5D) . Conjointly, these data indicate that AMPK is a vital kinase for cells against energy deprivation and cytotoxicity during parthanatos.
Diminished mitochondrial activity in Atg5
−/− MEFs in response to parthanatos
Considering the versatility of AMPK, we first intuitively tested whether mitochondrial signaling and activity are an inevitable part of AMPK-mediated cytoprotective effects against parthanatos via SIRT1 and mitochondrial biogenesis [28] . At 8 h after MNNG administration, when the ATP level in WT MEFs was ready for a significant rebound yet not in Atg5 −/− MEFs (Fig. 1A) , we consistently observed that SIRT1 activity was rather impaired in Atg5 −/− MEFs but not significantly affected in WT counterpart (Fig. 6A) . We also noted here that Atg5
MEFs harbored an inherently compromised SIRT1 activity at basal level (about 80% compared to WT; Fig. 6A ). However, with addition of PD98059, SIRT1 activity was significantly elevated in both MNNGchallenged WT and Atg5 −/− MEFs (Fig. 6A ). In line with the necessity of SIRT1, pharmacologic inhibition of SIRT1 by sirtinol completely amplified MNNG cytotoxicity in both WT and Atg5 −/− MEFs (Fig. 6B) .
With a check in mitochondrial DNA (mtDNA) content, however, we found that MNNG was able to increase mtDNA content at 1 h in both WT and Atg5 −/− MEFs, but the intensity was attenuated thereafter (Fig. 6C) . Besides, a higher mtDNA induction was noted in Atg5
MEFs than in the WT counterpart in response to MNNG (Fig. 6C) . We reasoned that this compensatory higher burst was reflective of intrinsic deficiencies in mitochondrial quality control in Atg5 −/− MEFs, even though it was still not comparable for providing sufficient energy resources from these defective mitochondria during parthanatos. In the presence of PD98059, we observed that a higher induction fold and a longer retention intensity of mtDNA content were achieved in both WT and Atg5 −/− MEFs after MNNG challenge (Fig. 6C) . Furthermore, we also noticed that, in both WT and Atg5 −/− MEFs, PD98059 alone was capable of stimulating mtDNA synthesis (Fig. 6C ) and raising the transcription of peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1 alpha (PGC1α) (Fig. 6D) , whose product is a master regulator of mitochondrial gene expression and energy metabolism [29] .
To further confirm the mitochondrial setting for energy restoration after MNNG challenge, we used the mitochondrial pharmacologic inhibitors rotenone (a complex I/II inhibitor), DPI (a flavoprotein inhibitor), and FCCP (a mitochondrial uncoupler). In the presence of rotenone, DPI or FCCP, MNNG cytotoxicity was extremely exasperated in both WT and Atg5 −/− MEFs (Fig. 6E) . Of note, all of these mitochondrial inhibitors alone did not lead to differential energy level between WT and Atg5 −/− MEFs at 24 h treatment (Fig. 6E) . For a close view about the ATP-depleting process, we found that the ATP level was severely exhausted in the presence of rotenone or DPI in both WT and Atg5
−/−
MEFs as early as 15 min after MNNG challenge and without subsequent rebound (Fig. 6F) . On the other hand, we also utilized the MTT, a tetrazolium dye which could be converted into a purple formazan by the mitochondrial succinate dehydrogenase in viable cells as an indicator of mitochondrial activity. Concordantly, MNNG challenge decreased MTT activity to higher extent in Atg5 −/− MEFs than in the WT counterpart (Fig. 6G) . In 1 h MNNG treatment, the MTT activities were equally suppressed to half their basal levels, but thereafter, this compromised mitochondrial activity was relieved in WT MEFs while continuously suppressed in Atg5 −/− MEFs (Fig. 6G) . Moreover, addition of PD98059 better recovered mitochondrial activity in Atg5 −/− MEFs 10 h after MNNG administration, but not significantly improved further in WT MEFs (Fig. 6G) . To determine whether necrotic events preceded the early suppression of ATP level and mitochondrial activity, we used the JC-1 dye to evaluate the mitochondrial transmembrane potential (△ Ψ m ), whose dissipation is a common signature of mitochondrial depolarization in necrotic cell death. Intriguingly, △ Ψ m dissipation was undetectable at 1, 4, and 8 h after MNNG challenge in both WT and Atg5 −/− MEFs (Fig. 6H ), yet the validity of experiment was confirmed by the positive controls using FCCP and rotenone with detectable dissipation occurring as early as in 4 h treatment in Atg5 −/− MEFs (Fig. 6H) . Collectively, these results suggest that mitochondrial activity predetermines the tolerability of cells to MNNG and unveil its diminished activity in Atg5 −/− MEFs during parthanatos.
Autophagic flux is not obligatory for energy supply and protection during parthanatos
With observations on a requirement of AMPK in energy adaptation and the susceptibility of Atg5 −/− MEFs, together with the notion for the involvement of AMPK in autophagy induction [30] , we reasonably speculated a role of autophagy during parthanatos. In the presence of bafilomycin A1, a vacuolar H + ATPase inhibitor that prevents autolysosomal fusion, we found, however, that MNNG did not promote LC3 lipidation, a molecular signature of autophagosome maturation. Consistently MNNG did not induce p62 degradation, a consequence of cargo elimination within autolysosomal compartment, in WT MEFs without bafilomycin A1 treatment. Noticeably, the defective autophagy induction machinery in Atg5 −/− MEFs was confirmed by the absence of lipidated (LC3-II) and the p62 accumulation (Fig. 7A) . Consistently, we did neither observe LC3 lipidation in HeLa cells after MNNG challenge (Fig. 7B) , while a gradual decline in expression of LC3-II was noted (Fig. 7B) . Much strikingly, MNNG-mediated ATP response curves and cytotoxicity were not exacerbated in the presence of bafilomycin A1 in both WT and Atg5 −/− MEFs (Figs. 7C and D) . Compatibly with above, the addition of PD98059 still facilitated ATP recovery in WT and Atg5 −/− MEFs in the presence of bafilomycin A1 after MNNG administration (Fig. 7E) . Therefore, these results together with Fig. 6 indicate that parthanatos does not induce autophagic flux but is aggravated by the deficits in mitochondrial quality control underlying Atg5 deficiency. 
Discussion
Massive NAD + and ATP depletion is a general mark of PARP1-mediated necrotic cell death. Despite the current progress that exogenous supplementation of metabolic intermediates could save neurons or glia cells from PARP1-mediated cell death [15, 16, 31, 32] , less is known about the regulation of energy turnover during the parthanatos. Here, we characterized the depleting and recovering phases of ATP level during parthanatos and underscored the recovery capability as a determinant of severity of parthanatic cell death. By using macroautophagy-defective Atg5 −/− MEFs, we highlighted their extraordinary vulnerability to the alkylating agent MNNG, but not to the DNA-intercalating topoisomerase II inhibitors doxorubicin and etoposide, which could potently initiate apoptotic cell death [33] . Regarding a potential dual role of Atg5 in autophagy and apoptosis [34] , our observed fragility and impaired ATP restorability of Atg5 −/− MEFs to MNNG were unaffected by the pan-caspase inhibitor zVAD-fmk, together with the unequivocally similar responses of WT and Atg5 −/− MEFs to doxorubicin suggesting that Atg5 deficiency confers a specific infirmity to parthanatos.
Our findings indicate that the MAPK signaling pathways are not involved in the regulation of parthanatic energy responses, albeit their reported modalities elsewhere to DNA repair, cell cycle arrest, and defense response to stress [13, 14, 35, 36] . Furthermore, both WT and Atg5 −/− MEFs showed comparable MAPK activation during parthanatos, possibly excluding a link underlying Atg5 deficiency to those activation. A MEK-independent PD98059 protectiveness from parthanatos is exceptionally highlighted throughout this study. The differential actions between the conventional MEK kinase inhibitors PD98059 and U0126 have been reported somewhere in literature, where, for example, PD98059 could potently stimulate adipogenesis but U0126 did not [37] . In line with their findings, here we also showed that only PD98059 administration effectively saved MEFs from parthanatos. Indeed, several MEK-independent actions for PD98059 have been reported and might be correlated to its property as a flavonoid derivative, including weak estrogenic activity [37, 38] , elevation of glutathione [39] [40] [41] , and behaving as an aryl hydrocarbon receptor (AHR) antagonist [42] . Notably, in this study we implied that PD98059 protectiveness from parthanatos comes from an enhancement of mitochondrial activity, without modulation on the DNA damage responses. Therefore, from our results in combination with previous findings [37, 38] and a body of knowledge that links estrogenic activities to mitochondrial respiration [43] [44] [45] , we believe that PD98059 is able to boost up mitochondrial functionality which seems extremely essential to energy restoration during parthanatos. AMPK is a multifunctional protein kinase that participates in energy expenditure and autophagy induction in response to diverse stimuli [30, 46] . In this study we uncovered an absolute requirement of AMPK to protect cells from parthanatos and dissected its potential downstream cellular processes [28, 47, 48] , i.e., underlining the importance of mitochondrial metabolism but, unexpectedly, not of autophagy induction as an adaptive response to parthanatos. The unnecessariness of autophagic flux machinery for energy restoration during parthanatos was also exemplified in our study by the absence of LC3 lipidation and p62 elimination after MNNG challenge, the parthanatos irresponsive to bafilomycin A1, as well as parthanatos insensitive to enforced autophagy induction by mTORC1 inhibition, which is supposed to be responsible for autophagy induction downstream of AMPK activation [49] . Furthermore, the PD98059 protectiveness was also rechecked to be independent of autophagy induction as illustrated with its effectiveness in the presence of bafilomycin A1. In this study, we also observed the higher basal AMPK signaling in Atg5 −/− MEFs. We reasoned that the increased AMPK activity might be the compensatory adaptation in Atg5 −/− MEFs. However, an alternative macroautophagy has also been reported in Atg5 −/− MEFs in response to starvation or etoposide [50] , but here we precisely excluded the need of autophagy flux in parthanatos by use of the autophagy inhibitor bafilomycin A1, which shall block all the autophagic clearance events. After ruling out the necessity of autophagic flux in restoring mitochondrial activity and subsequent energy level during parthanatos, we reasoned that it is deficits in mitochondrial quality control associated with Atg5 knockout [51, 52] that contribute to impaired mitochondrial energy adaptability in response to this stress. In other setting, Stephenson et al. have shown that Atg5-dependent transcriptional changes were enriched in genes associated with mitochondrial maintenance by analyzing differentially expressed genes between WT and Atg5 −/− thymocytes [53] . Consistently here, we demonstrated that Atg5 −/− MEFs harbored an inherent diminishment in mitochondrial activity which is required for energy restoration and explainable for the vulnerability during parthanatos. Despite the currently unknown higher AMPKα1 phosphorylation status and the stronger mtDNA induction fold observed in our study, Atg5 −/− MEFs were still unable to well survive parthanatos owing to their intrinsic mitochondrial inadequacy. Even though PD98059 could dose-dependently and effectively recover ATP level in Atg5 −/− MEFs during parthanatos, this rescue was not comparable to the WT counterpart similarly due to their mitochondrial defects. Both SIRT1 and PARP1 consume NAD + to perform their major action, deacetylation and poly(ADP-ribosyl)ation, respectively [54] , and the functional interplay between them has also been documented. For instance, PARP1 over-activation was associated with subsequently reduced SIRT1 deacetylase activity leading to myocyte cell death during heart failure [55] . On the contrary, activation of SIRT1 dampened poly(ADP-ribose) polymerase activity of PARP1 whereas SIRT1 deficiency amplified PAR synthesis [56] . Furthermore, direct interaction between PARP1 and SIRT1 is also possible, such as SIRT1-dependent deacetylation on PARP1 to block PARP1 activity [57] . In this context, our data also support an inherent PARP1/SIRT1 imbalance in Atg5 −/− MEFs with an enhanced PAR signal and a decreased SIRT1 activity at the basal level, which may underlie their vulnerability to MNNG. Interestingly, we also observed that, in the presence of the PARP1 inhibitor 3AB or the absence of PARP1, administration of MNNG actually triggers an initial ATP burst exceeding the basal level within 8 h treatment. We reasoned that, under PARP1 inhibition when alkylated DNAs are still unresolved, a PARP1-independent machinery continues to operate, accounting for this surplus of ATP. Consistently with this phenomenon, PARP1 inhibition could increase mitochondrial content and energy expenditure through SIRT1 activation, rendering protection against several metabolic diseases as well as cancer [58] . However, considering the versatility and broad participation of SIRT1 and PARP1 under several physiologic and pathologic conditions [17, 59, 60] , the background metabolic status underlying SIRT1/PARP1 imbalance in Atg5 −/− MEFs is worthy of investigation to a greater extent, which may help clarify the interrelationship among SIRT1, PARP1, and macroautophagy, and benefit the treatment of many disorders linking to dysregulation in these aspects. Our results provide a complete energy perspective dealing with its regulation on the parthanatic response and explicitly point out the energy status as a key determinant in the death outcome. PARP1-mediated cell death has been frequently described in type I diabetes [10] , in neuropathology such as stroke [61] , excitotoxicity [61, 62] , and neurodegeneration [12, 21] , as well as at necrotic loci from ischemia-reperfusion injury like myocardial infarcts [63] . Concomitantly, autophagy dysregulation has also been implicated in these neurological and cardiovascular diseases [25, 64, 65] . In contrast, we clarify in this study a link of mitochondrial quality maintained by autophagy to the severity of parthanatos. Moreover, concerning the urgent need of efficacious PARP inhibitors for better therapeutic benefits within a wide range of inflammatory disorders [17] , we also identify unexpectedly PD98059 as a cytoprotective compound against parthanatos via enhancing mitochondrial metabolism and facilitating energy restoration following the ATP depletion. Taken together, our findings establish a fundamental basis for treating these parthanatos-related disorders and should guide the future direction for drug development.
